Literature DB >> 11085321

Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure.

D B Miller1, J P O'Callaghan, S F Ali.   

Abstract

A number of substituted amphetamines, including methamphetamine (METH) are considered dopaminergic neurotoxicants. METH causes long-term depletions of striatal dopamine (DA) and its metabolites (DOPAC and HVA) that are accompanied by other changes indicative of nerve terminal degeneration. These include argyrophilia as detected by silver degeneration stains and an elevation in glial fibrillary acidic protein (GFAP), a marker of reactive gliosis in response to injury, as well as a long-term decrease in tyrosine hydroxylase (TH) protein levels. The susceptibility to the dopaminergic neurotoxicity of METH and the other amphetamines can be affected by a number of factors including age, gender, stress, and environment. Many of these susceptibility factors have been extensively investigated in the rat but less so in the mouse. As the availability of genetically altered mice continues to expand, this species is increasingly selected for study. Thus, in previous work we determined that stress, gender, and the environment can significantly impact the neurotoxicity of the amphetamines. Here we determined how age affects the striatal DA depletion and GFAP elevation induced by d-METH in C57BL/6 mice. Age was a significant determinant of the ability of a known neurotoxic regimen of d-METH (10 mg/kg x 4) to produce striatal DA depletion with one-month-old C57BL16 mice displaying minimal and nonpersistent depletion of DA or its metabolites while mice 12 months of age displayed large and persistent depletions of DA (87%), DOPAC (71%), and HVA (94%). Large elevations in striatal GFAP were induced in mice 2-23 months of age by d-METH, with lower dosages of d-METH being effective in the older mice. In contrast, the usual neurotoxic regimen of d-METH was minimally effective in inducing GFAP elevations (49% over control) in one-month-old mice, despite elevations in body temperature equivalent to those observed in older mice. Although increasing the dosage of d-METH (20 to 80 mg/kg) did increase the GFAP response (100% over control), it was still well below that usually exhibited at the usual neurotoxic dosage (300-400% over control) in fully mature mice. These data suggest maturity of striatal dopamine systems may be an essential element in the striatal damage induced by the neurotoxic amphetamines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085321     DOI: 10.1111/j.1749-6632.2000.tb05196.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  10 in total

Review 1.  Potential adverse effects of amphetamine treatment on brain and behavior: a review.

Authors:  S M Berman; R Kuczenski; J T McCracken; E D London
Journal:  Mol Psychiatry       Date:  2008-08-12       Impact factor: 15.992

2.  Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence.

Authors:  N D Volkow; L Chang; G J Wang; J S Fowler; D Franceschi; M Sedler; S J Gatley; E Miller; R Hitzemann; Y S Ding; J Logan
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

3.  Methamphetamine-induced locomotor changes are dependent on age, dose and genotype.

Authors:  Renee L Good; Richard A Radcliffe
Journal:  Pharmacol Biochem Behav       Date:  2010-12-14       Impact factor: 3.533

4.  Mouse strain- and age-dependent effects of binge methamphetamine on dopaminergic signaling.

Authors:  Renee L Good; Li-Ping Liang; Manisha Patel; Richard A Radcliffe
Journal:  Neurotoxicology       Date:  2011-07-20       Impact factor: 4.294

5.  Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson's disease.

Authors:  C Venkateshappa; G Harish; Rajeswara Babu Mythri; Anita Mahadevan; M M Srinivas Bharath; S K Shankar
Journal:  Neurochem Res       Date:  2011-10-05       Impact factor: 3.996

Review 6.  Abuse of amphetamines and structural abnormalities in the brain.

Authors:  Steven Berman; Joseph O'Neill; Scott Fears; George Bartzokis; Edythe D London
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

7.  The Impact of Depressive Symptoms on Neuropsychological Performance Tests in HIV-Infected Individuals: A Study of the Hawaii Aging with HIV Cohort.

Authors:  Sheri M Shimizu; Dominic C Chow; Victor Valcour; Kamal Masaki; Beau Nakamoto; Kalpana J Kallianpur; Cecilia Shikuma
Journal:  World J AIDS       Date:  2011-12-01

8.  Effect of a neurotoxic dose regimen of (+)-methamphetamine on behavior, plasma corticosterone, and brain monoamines in adult C57BL/6 mice.

Authors:  Curtis E Grace; Tori L Schaefer; Nicole R Herring; Devon L Graham; Matthew R Skelton; Gary A Gudelsky; Michael T Williams; Charles V Vorhees
Journal:  Neurotoxicol Teratol       Date:  2010-01-21       Impact factor: 3.763

9.  Long-term effects of a single adult methamphetamine challenge: minor impact on dopamine fibre density in limbic brain areas of gerbils.

Authors:  Susanne Brummelte; Thorsten Grund; Andrea Czok; Gertraud Teuchert-Noodt; Jörg Neddens
Journal:  Behav Brain Funct       Date:  2006-03-28       Impact factor: 3.759

Review 10.  The effects of adolescent methamphetamine exposure.

Authors:  Jordan M Buck; Jessica A Siegel
Journal:  Front Neurosci       Date:  2015-04-29       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.